Health Catalyst, Inc. (NASDAQ:HCAT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Health Catalyst, Inc. (NASDAQ:HCATGet Rating) has earned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $25.92.

Several equities research analysts recently commented on HCAT shares. The Goldman Sachs Group reduced their price target on shares of Health Catalyst from $29.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 10th. BTIG Research dropped their target price on shares of Health Catalyst from $35.00 to $25.00 in a research note on Wednesday, July 27th. Piper Sandler downgraded shares of Health Catalyst from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $21.00 to $11.00 in a research note on Tuesday. JPMorgan Chase & Co. cut shares of Health Catalyst from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $20.00 to $16.00 in a report on Friday, August 5th. Finally, Stifel Nicolaus lowered shares of Health Catalyst from a “buy” rating to a “hold” rating and cut their price objective for the stock from $27.00 to $16.00 in a research report on Friday, August 5th.

Insider Activity at Health Catalyst

In other news, Director Duncan Gallagher acquired 8,400 shares of the business’s stock in a transaction on Thursday, August 18th. The shares were purchased at an average cost of $11.69 per share, with a total value of $98,196.00. Following the acquisition, the director now directly owns 28,805 shares of the company’s stock, valued at $336,730.45. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Health Catalyst

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HCAT. Capital Research Global Investors boosted its stake in Health Catalyst by 8.8% in the fourth quarter. Capital Research Global Investors now owns 3,392,000 shares of the company’s stock worth $134,391,000 after buying an additional 275,700 shares in the last quarter. Alliancebernstein L.P. lifted its position in Health Catalyst by 42.8% in the fourth quarter. Alliancebernstein L.P. now owns 3,124,879 shares of the company’s stock valued at $123,808,000 after purchasing an additional 936,784 shares during the last quarter. Clearbridge Investments LLC lifted its position in Health Catalyst by 3.3% in the first quarter. Clearbridge Investments LLC now owns 2,317,997 shares of the company’s stock valued at $60,569,000 after purchasing an additional 73,852 shares during the last quarter. abrdn plc lifted its position in Health Catalyst by 31.4% in the first quarter. abrdn plc now owns 1,442,584 shares of the company’s stock valued at $37,695,000 after purchasing an additional 345,137 shares during the last quarter. Finally, Riverbridge Partners LLC lifted its position in Health Catalyst by 9.8% in the first quarter. Riverbridge Partners LLC now owns 1,222,571 shares of the company’s stock valued at $31,946,000 after purchasing an additional 109,115 shares during the last quarter. 96.58% of the stock is currently owned by institutional investors.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT opened at $10.32 on Friday. The company has a market cap of $564.74 million, a PE ratio of -3.53 and a beta of 1.23. Health Catalyst has a 52 week low of $10.21 and a 52 week high of $57.19. The firm has a 50 day simple moving average of $13.69 and a 200 day simple moving average of $17.16.

Health Catalyst (NASDAQ:HCATGet Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.09. The business had revenue of $70.63 million during the quarter, compared to the consensus estimate of $69.78 million. Health Catalyst had a negative net margin of 54.64% and a negative return on equity of 18.31%. On average, equities analysts predict that Health Catalyst will post -1.82 earnings per share for the current year.

Health Catalyst Company Profile

(Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.

Read More

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.